Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Pharmaceutical
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
BERKELEY HEIGHTS, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic...
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on...
Evaxion Announces Business Update and First Quarter 2024 Financial Results
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio...
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients...
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full...
Longeveron® to Attend BIO International Convention 2024
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular...
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet...
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762
Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May...
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's diseaseOne of Evotec's largest strategic drug...
Red Light Holland Completes First Phase of Natural Psilocybin Extraction with PharmAla, Initiates Optimization Process
Toronto, Ontario--(Newsfile Corp. - May 27, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
IRLAB Appoints Kristina Torfgård as New CEO
GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics...
Cosmo Pharmaceuticals’ Shareholders Approve All Agenda Items at Annual General Meeting
Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that its...
FSD Pharma Provides Corporate Update
TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q
CHICAGO, IL / ACCESSWIRE / May 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 studyIRVINE, Calif., May 24,...
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T...
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic...